Previous research has demonstrated constitutive activity of NF-κB, or mutations in genes encoding upstream regulators of NF-κB, in a significant number of human cancers, especially those of immune cell origin, such as leukemias and lymphomas. This evidence concerns the gene NFKB1 and lymphoma.